Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir vs Efavirenz in HIV-Infected Women
NCT00984152Phase 3Withdrawn
- Sponsor
- Rush University Medical Center
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Rush University Medical Center. Primary endpoints: Viral load in plasma, genital tract, and gut at 48 weeks, Latent viral reservoir (pro-viral DNA) at 48 weeks and 1 more. Planned start Jun 2011; status: withdrawn.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00984152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984152.